EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

Search

Sanofi SA

Closed

Sector Healthcare

90.88 0.04

Overview

Share price change

24h

Current

Min

90.2

Max

91.02

Key metrics

By Trading Economics

Income

1.7B

2.8B

Sales

2.1B

13B

P/E

Sector Avg

30.62

94.998

EPS

2.86

Dividend yield

3.944

Profit margin

20.945

EBITDA

2.2B

4.2B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+23.16 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.94%

2.40%

Next Earnings

30 Jan 2025

Market Stats

By TradingEconomics

Market Cap

113B

Previous open

90.84

Previous close

90.88

News Sentiment

By Acuity

34%

66%

100 / 392 Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

15 Nov 2024, 10:28 UTC

Major Market Movers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

29 Oct 2024, 10:07 UTC

Earnings

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 Oct 2024, 06:37 UTC

Earnings

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

28 Oct 2024, 16:07 UTC

Acquisitions, Mergers, Takeovers

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 Oct 2024, 05:44 UTC

Earnings

Sanofi Profit, Sales Beat Estimates

15 Nov 2024, 13:08 UTC

Top News

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 Nov 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

15 Nov 2024, 10:29 UTC

Hot Stocks

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

14 Nov 2024, 11:29 UTC

Market Talk
Earnings

European Banks' Results Confirm Earnings Momentum -- Market Talk

4 Nov 2024, 11:42 UTC

Market Talk

European Banks Exposed to Trade Tariffs Outcome From U.S. Election -- Market Talk

29 Oct 2024, 13:16 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 Oct 2024, 07:02 UTC

Market Talk

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 Oct 2024, 05:52 UTC

Earnings

Santander Backs 2024 View

29 Oct 2024, 05:52 UTC

Earnings

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 Oct 2024, 05:51 UTC

Earnings

Santander Confident on Delivering on Targets

29 Oct 2024, 05:50 UTC

Earnings

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 Oct 2024, 05:50 UTC

Earnings

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 Oct 2024, 05:49 UTC

Earnings

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 Oct 2024, 05:49 UTC

Earnings

Santander 3Q Net Interest Income EUR11.225B

29 Oct 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Net Loan Loss Provisions EUR3.17B

29 Oct 2024, 05:48 UTC

Earnings

Santander 3Q Net Loan Loss Provisions EUR2.98B

29 Oct 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Net Pft EUR3.17B

29 Oct 2024, 05:48 UTC

Earnings

Santander 3Q Net Pft EUR3.25B

29 Oct 2024, 05:48 UTC

Earnings

Santander 3Q Rev EUR15.135B

29 Oct 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Rev EUR15.31B

28 Oct 2024, 08:18 UTC

Market Talk

Banks' Risks From U.K. Motor Finance Probe Rise -- Market Talk

25 Oct 2024, 20:25 UTC

Earnings

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 Oct 2024, 13:12 UTC

Earnings

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 Oct 2024, 07:00 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 Oct 2024, 05:30 UTC

Earnings

Sanofi 3Q Adj EPS EUR2.86

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

23.16% upside

12 Months Forecast

Average 112.335 EUR  23.16%

High 130 EUR

Low 90 EUR

Based on 13 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

90.82 / 95.65Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

100 / 392 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.